Although those in pharma often dislike any references to drugs competing with each other for market as in a ‘race’, it’s inevitable that such allusions will be drawn between rivals.
Gilead’s recent acquisition, Kite Pharma, is one of two CAR-T therapies to receive approvals, alongside Novartis’ Kymriah, and comparing it to an arm’s race is the temptation. If that were the case, Kite’s recent team up with Pfizer looks set to test whether its treatment can go nuclear on refractory large B-cell lymphoma.
